[8-K] MiNK Therapeutics, Inc. Reports Material Event
MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025 and furnished a related press release as Exhibit 99.1 to this Current Report on Form 8-K. The filing states that the information under Item 2.02 and Exhibit 99.1 is being furnished and therefore is not intended to be deemed filed for purposes of Section 18 of the Exchange Act. The 8-K itself does not include the underlying financial figures; the press release referenced in Exhibit 99.1 contains the detailed results and the Cover Page Interactive Data File is included as Exhibit 104.
MiNK Therapeutics, Inc. ha annunciato i risultati finanziari per il trimestre chiuso al 30 giugno 2025 e ha trasmesso il relativo comunicato stampa come Exhibit 99.1 nel presente Current Report on Form 8-K. Il documento specifica che le informazioni sotto Item 2.02 e nell'Exhibit 99.1 sono state fornite e non sono dunque intese come depositate ai fini della Section 18 dello Exchange Act. Il modulo 8-K non contiene le cifre finanziarie sottostanti; il comunicato citato nell'Exhibit 99.1 riporta i risultati dettagliati e il Cover Page Interactive Data File 猫 incluso come Exhibit 104.
MiNK Therapeutics, Inc. anunci贸 sus resultados financieros del trimestre cerrado el 30 de junio de 2025 y adjunt贸 el comunicado de prensa correspondiente como Exhibit 99.1 en este Current Report on Form 8-K. La presentaci贸n indica que la informaci贸n bajo el Item 2.02 y el Exhibit 99.1 se ha proporcionado y, por tanto, no debe considerarse presentada a efectos de la Section 18 del Exchange Act. El 8-K en s铆 no incluye las cifras financieras subyacentes; el comunicado referido en el Exhibit 99.1 contiene los resultados detallados y el Cover Page Interactive Data File se incluye como Exhibit 104.
MiNK Therapeutics, Inc.電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞛 鞁れ爜鞚� 氚滍憸頄堨溂氅�, 甏�霠� 氤措弰鞛愲毳� 鞚� Current Report on Form 8-K鞚� Exhibit 99.1搿� 鞝滌稖頃橃榾鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 Item 2.02鞕� Exhibit 99.1鞐� 韽暔霅� 鞝曤炒臧� 鞝滉车霅� 瓴冹澊氅� 霐半澕靹� Exchange Act鞚� Section 18鞐� 霐半澕 鞝滌稖霅� 瓴冹溂搿� 臧勳＜霅橃 鞎婋姅雼�瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 8-K鞐愲姅 旮半掣 鞛 靾橃箻臧� 韽暔霅橃柎 鞛堨 鞎婌溂氅�, Exhibit 99.1鞚� 氤措弰鞛愲鞐� 靸侅劯頃� 鞁れ爜鞚� 旮办灛霅橃柎 鞛堦碃 Cover Page Interactive Data File鞚� Exhibit 104搿� 觳秬霅橃柎 鞛堨姷雼堧嫟.
MiNK Therapeutics, Inc. a annonc茅 ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 et a transmis le communiqu茅 de presse correspondant en tant qu'Exhibit 99.1 dans ce Current Report on Form 8-K. Le d茅p么t pr茅cise que les informations figurant 脿 l'Item 2.02 et dans l'Exhibit 99.1 ont 茅t茅 fournies et ne sont donc pas destin茅es 脿 锚tre consid茅r茅es comme 诲茅辫辞蝉茅别蝉 au sens de la Section 18 de l'Exchange Act. Le formulaire 8-K lui-m锚me n'inclut pas les montants financiers sous-jacents ; le communiqu茅 mentionn茅 en Exhibit 99.1 contient les r茅sultats d茅taill茅s et le Cover Page Interactive Data File est inclus en tant qu'Exhibit 104.
MiNK Therapeutics, Inc. gab seine Finanzergebnisse f眉r das Quartal zum 30. Juni 2025 bekannt und legte die zugeh枚rige Pressemitteilung als Exhibit 99.1 zu diesem Current Report on Form 8-K vor. Die Einreichung stellt klar, dass die Informationen in Item 2.02 und Exhibit 99.1 bereitgestellt wurden und daher nicht als eingereicht im Sinne von Section 18 des Exchange Act gelten sollen. Das 8-K selbst enth盲lt nicht die zugrunde liegenden Finanzzahlen; die in Exhibit 99.1 referenzierte Pressemitteilung enth盲lt die detaillierten Ergebnisse und die Cover Page Interactive Data File ist als Exhibit 104 beigef眉gt.
- Press release furnished as Exhibit 99.1, indicating timely public disclosure of quarterly results
- Inline XBRL cover page (Exhibit 104) included, supporting data tagging and accessibility
- No financial figures are provided in the 8-K text itself; readers must consult Exhibit 99.1 for the results
- Furnished, not filed status limits Section 18 liability and may affect legal recourse regarding the disclosed information
Insights
TL;DR: The company publicly disclosed quarterly results via a furnished press release; the 8-K contains no financial detail itself.
The filing formally notifies investors that MiNK Therapeutics announced results for the quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1. The disclosure explicitly states the press release is furnished, not filed, limiting Section 18 liabilities. Because the 8-K does not include numeric financial data, material assessment relies on the content of Exhibit 99.1 rather than this form alone.
TL;DR: Formally furnishing a press release is a routine disclosure step; the 8-K itself contains no new financial metrics.
From a governance and disclosure perspective, the company followed standard procedures by furnishing its earnings press release and including Inline XBRL cover page data. The filing clarifies the legal status of the furnished materials. The form does not present balance sheet, income statement, or MD&A text, so the governance implications are limited to timely public disclosure practice rather than substantive financial change.
MiNK Therapeutics, Inc. ha annunciato i risultati finanziari per il trimestre chiuso al 30 giugno 2025 e ha trasmesso il relativo comunicato stampa come Exhibit 99.1 nel presente Current Report on Form 8-K. Il documento specifica che le informazioni sotto Item 2.02 e nell'Exhibit 99.1 sono state fornite e non sono dunque intese come depositate ai fini della Section 18 dello Exchange Act. Il modulo 8-K non contiene le cifre finanziarie sottostanti; il comunicato citato nell'Exhibit 99.1 riporta i risultati dettagliati e il Cover Page Interactive Data File 猫 incluso come Exhibit 104.
MiNK Therapeutics, Inc. anunci贸 sus resultados financieros del trimestre cerrado el 30 de junio de 2025 y adjunt贸 el comunicado de prensa correspondiente como Exhibit 99.1 en este Current Report on Form 8-K. La presentaci贸n indica que la informaci贸n bajo el Item 2.02 y el Exhibit 99.1 se ha proporcionado y, por tanto, no debe considerarse presentada a efectos de la Section 18 del Exchange Act. El 8-K en s铆 no incluye las cifras financieras subyacentes; el comunicado referido en el Exhibit 99.1 contiene los resultados detallados y el Cover Page Interactive Data File se incluye como Exhibit 104.
MiNK Therapeutics, Inc.電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞛 鞁れ爜鞚� 氚滍憸頄堨溂氅�, 甏�霠� 氤措弰鞛愲毳� 鞚� Current Report on Form 8-K鞚� Exhibit 99.1搿� 鞝滌稖頃橃榾鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 Item 2.02鞕� Exhibit 99.1鞐� 韽暔霅� 鞝曤炒臧� 鞝滉车霅� 瓴冹澊氅� 霐半澕靹� Exchange Act鞚� Section 18鞐� 霐半澕 鞝滌稖霅� 瓴冹溂搿� 臧勳＜霅橃 鞎婋姅雼�瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 8-K鞐愲姅 旮半掣 鞛 靾橃箻臧� 韽暔霅橃柎 鞛堨 鞎婌溂氅�, Exhibit 99.1鞚� 氤措弰鞛愲鞐� 靸侅劯頃� 鞁れ爜鞚� 旮办灛霅橃柎 鞛堦碃 Cover Page Interactive Data File鞚� Exhibit 104搿� 觳秬霅橃柎 鞛堨姷雼堧嫟.
MiNK Therapeutics, Inc. a annonc茅 ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 et a transmis le communiqu茅 de presse correspondant en tant qu'Exhibit 99.1 dans ce Current Report on Form 8-K. Le d茅p么t pr茅cise que les informations figurant 脿 l'Item 2.02 et dans l'Exhibit 99.1 ont 茅t茅 fournies et ne sont donc pas destin茅es 脿 锚tre consid茅r茅es comme 诲茅辫辞蝉茅别蝉 au sens de la Section 18 de l'Exchange Act. Le formulaire 8-K lui-m锚me n'inclut pas les montants financiers sous-jacents ; le communiqu茅 mentionn茅 en Exhibit 99.1 contient les r茅sultats d茅taill茅s et le Cover Page Interactive Data File est inclus en tant qu'Exhibit 104.
MiNK Therapeutics, Inc. gab seine Finanzergebnisse f眉r das Quartal zum 30. Juni 2025 bekannt und legte die zugeh枚rige Pressemitteilung als Exhibit 99.1 zu diesem Current Report on Form 8-K vor. Die Einreichung stellt klar, dass die Informationen in Item 2.02 und Exhibit 99.1 bereitgestellt wurden und daher nicht als eingereicht im Sinne von Section 18 des Exchange Act gelten sollen. Das 8-K selbst enth盲lt nicht die zugrunde liegenden Finanzzahlen; die in Exhibit 99.1 referenzierte Pressemitteilung enth盲lt die detaillierten Ergebnisse und die Cover Page Interactive Data File ist als Exhibit 104 beigef眉gt.
FAQ
What did MiNK Therapeutics (INKT) disclose in this 8-K?
Are the financial results included directly in the 8-K?
Is the press release considered filed or furnished?
Where can I find the detailed earnings information referenced in the 8-K?
Who signed the Form 8-K for MiNK Therapeutics?
